KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Cash & Equivalents (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Cash & Equivalents for 11 consecutive years, with $50.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 8.98% to $50.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.2 million through Dec 2025, down 8.98% year-over-year, with the annual reading at $50.2 million for FY2025, 8.98% down from the prior year.
  • Cash & Equivalents hit $50.2 million in Q4 2025 for Fulgent Genetics, down from $117.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $353.1 million in Q1 2022 to a low of $24.0 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $104.8 million across 5 years, with a median of $86.0 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: soared 4032.5% in 2021 and later plummeted 92.4% in 2023.
  • Year by year, Cash & Equivalents stood at $164.9 million in 2021, then crashed by 51.78% to $79.5 million in 2022, then rose by 22.6% to $97.5 million in 2023, then crashed by 43.43% to $55.1 million in 2024, then dropped by 8.98% to $50.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for FLGT at $50.2 million in Q4 2025, $117.6 million in Q3 2025, and $87.9 million in Q2 2025.